Hugh James Freeman*

Department of Medicine (Gastroenterology), University of British Columbia, Vancouver, BC, Canada

*Corresponding Author: Hugh James Freeman, Department of Medicine (Gastroenterology), University of British Columbia, Vancouver, BC, Canada.

Received: February 19, 2024; Published: February 28, 2024

Abstract

Cardiolipin antibodies have been considered to be a hallmark or marker of the antiphospholipid syndrome, a disorder associated with an increased risk of cerebrovascular events and pregnancy loss. Prior studies have shown increased cardiolipin antibodies in celiac disease, and even higher in some studies of treated celiac disease with a gluten-free diet. Still, limited clinical follow-up in these studies did not permit exploration of an increased risk of cardiovascular events. This study explored this paradigm in 28 celiac disease patients, treated with a gluten-free diet, defined by histopathological evidence of normalization of small intestinal mucosa. Here, in celiacs on a lifelong gluten-free diet, no increased cardiovascular risk, as reflected in clinically evident thrombotic or embolic events, was identified despite follow-up for up to 34 years. Cardiolipin antibodies in gluten-free diet treated celiac disease could represent a marker of risk, but this was defined here despite long-term clinical follow-up over many decades.

 Keywords: Anti-cardiolipin Antibodies; Celiac Disease; Antiphospholipid Syndrome; IgG and IgM Antibodies; Hypercoagulability in Celiac Disease

References

1. Levine JS., et al. “The antiphospholipid syndrome”. The New England Journal of Medicine 346 (2002): 752-763.
2. Garcia D and Erkan D. “Diagnosis and management of the antiphospholipid syndrome”. The New England Journal of Medicine 378 (2018): 2010-2021.
3. Wassermann A., et al. “Eine serodiagnostiche Reaktion bei Syphilis”. Deutsche Med Wochenschr 32 (1906): 745-746.
4. Harris RG., et al. “Anticardiolipid antibodies: an elderly statesman dons new garments”. Journal of Rheumatology13 (1987): 208-213.
5. Alarcon-Segovia D., et al. “Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus”. Seminars in Arthritis and Rheumatism 21 (1992): 275-286.
6. Ginsburg KS., et al. “Anti-cardiolipin antibodies and the risk for ischemic stroke and venous thrombosis”. Annals of Internal Medicine 117 (1992): 997-1002.
7. Vaarala O., et al. “Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men”. Circulation 91 (1995): 23-27.
8. Levine SR., et al. “Risk of recurrent thromboembolic events in patients with focal cerebral schema and anti-phospholipid antibodies”. Stroke 23 (1992): I-29-I-32.
9. Lerner A., et al. “Increased prevalence of autoantibodies in celiac disease”. Digestive Diseases and Sciences 43 (1998): 723-726.
10. Shamir R., et al. “The prevalence of celiac disease antibodies in patients with the antiphospholipid syndrome”. Lupus 12 (2003): 394-399.
11. Freeman HJ. “Mucosal recovery and mucosal healing in biopsy-defined adult celiac disease”. International Journal of Celiac Disease 5 (2017): 14-18.
12. Merkel PA., et al. “The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases”. American Journal of Medicine 101 (1996): 576-583.
13. Perera DR., et al. “Symposium on pathology of the gastrointestinal tract. Part II. Small intestinal biopsy”. Human Pathology 6 (1975): 157-217.
14. Marsh MN. “Gluten, major histocompatibility complex and the small intestine. A molecular and immunobiologic approach to the spectrum of gluten sensitivity (“celiac sprue”)”. Gastroenterology 102 (1992): 330-354.
15. Corazza GR., et al. “Comparison of the intraobserver reproducibility with different histologic criteria used in celiac disease”. Clinical Gastroenterology and Hepatology 5 (2007): 838-843.
16. Freeman HJ. “Pearls and pitfalls in the diagnosis of celiac disease”. Canadian Journal of Gastroenterology 22 (2008): 273-280.
17. Alba P., et al. “Celiac disease and antiphospholipid syndrome: a case report”. Revista de la Facultad de Ciencias Médicas de Córdoba 66 (2009): 73-76.
18. Gupta D and Mirza N. “Systemic lupus erythematosus, celiac disease and antiphospholipid syndrome: a rare association”. Rheumatology International 28 (2008): 1179-1180.
19. Lerner A and Blank M. “Hypercoagulability in celiac disease—an update”. Autoimmune Review 13 (2014): 1138-1141.
20. Shamir R., et al. “The prevalence of celiac disease antibodies in patients with the antiphospholipid syndrome”. Lupus 12 (20): 03394-399.
21. Karoui S., et al. “Prevalence of anticardiolipin and anti-beta2-glycoprotein I antibodies in celiac disease”. Digestive Diseases and Sciences 52 (2007): 1096-1100.
22. Mankai A., et al. “Anti-cardiolipin and anti-beta2-glycoprotein I antibodies in celiac disease”. Pathologie-biologie (Paris) 60 (2012): 291-295.
23. Laine O., et al. “Elevated serum antiphospholipid antibodies in adults with celiac disease”. Digestive and Liver Disease 50 (2018): 457-461.

Citation

Citation: Hugh James Freeman. “Cardiolipin Antibodies in Biopsy-defined Adult Celiac Disease”.Acta Scientific Medical Sciences 8.3 (2024): 136-139.

Copyright

Copyright: © 2024 Hugh James Freeman. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.